Close Menu

    Subscribe to Updates

    Get the latest tech news from Tallwire.

      What's Hot

      Federal Reserve Warns AI Agents Could Trigger Bank Runs in Minutes, Threatening Financial Stability

      November 21, 2026

      Google Warns Autonomous AI Cyberattacks Have Arrived, Threatening U.S. Cybersecurity

      November 21, 2026

      Australia’s Greens Push 12-Month Smart Glasses Import Ban Over Privacy and Surveillance Concerns

      November 21, 2026
      Facebook X (Twitter) Instagram
      • Tech
      • AI
      • Get In Touch
      Facebook X (Twitter) LinkedIn
      TallwireTallwire
      • AI

        Google Warns Autonomous AI Cyberattacks Have Arrived, Threatening U.S. Cybersecurity

        November 21, 2026

        Federal Reserve Warns AI Agents Could Trigger Bank Runs in Minutes, Threatening Financial Stability

        November 21, 2026

        Paris Hilton Joins Bipartisan Push for DEFIANCE Act to Let AI Deepfake Victims Sue

        November 21, 2026

        Australia’s Greens Push 12-Month Smart Glasses Import Ban Over Privacy and Surveillance Concerns

        November 21, 2026

        Congressional Investigation Finds Major AI Platforms Can Generate Terrorist Attack Plans

        November 21, 2026
      • Tech

        Australia’s Greens Push 12-Month Smart Glasses Import Ban Over Privacy and Surveillance Concerns

        November 21, 2026

        CISA Warns Critical Java4Shell Security Flaw Could Allow Hackers to Hijack Computer Systems

        November 21, 2026

        Apple Pay, iCloud and App Store Outage Disrupts Thousands After Internal System Update

        November 20, 2026

        FAA’s $875 Million AI Air Traffic System Faces Scrutiny After Nationwide Flight Ground Stop

        November 19, 2026

        Uber Adds Amazon’s Zoox Robotaxis in Las Vegas, Escalating Driverless Car Competition With Waymo

        November 18, 2026
      • Business/Finance
      • Cybersecurity
      • Government
        • Legal
      • Health

        Medicare Delays Remote Patient Monitoring Restrictions Until 2029, Giving Tech Firms Reprieve

        November 11, 2026

        Anthropic’s AI Cancer Cure Claims Draw Scientific Skepticism as Drug Research Expands

        November 10, 2026

        Australia’s High Court Hears Constitutional Challenges to Social Media Ban

        November 7, 2026

        Majority of AI Health Users Trust Chatbots Over Doctors, Raising Patient Safety Concerns

        November 4, 2026

        Quantum Computing Breakthrough Could Transform AI Data Centers and Slash Energy Costs

        November 2, 2026
      • Science
        • Academia
      • Entertainment/Communications
      • People
      • Transportation
      • Opinion
      TallwireTallwire
      Home»Health»FDA Advisory Panel Unanimously Backs Moderna’s mRNA Flu Vaccine for Adults 50 and Older
      Health

      FDA Advisory Panel Unanimously Backs Moderna’s mRNA Flu Vaccine for Adults 50 and Older

      3 Mins Read
      Facebook Twitter Pinterest LinkedIn Tumblr Email
      Share
      Facebook Twitter LinkedIn Pinterest Email

      The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of Moderna’s investigational mRNA influenza vaccine, mFlusiva, for adults age 50 and older, significantly improving the vaccine’s prospects for regulatory approval later this summer. The vote follows months of scrutiny after regulators initially questioned the company’s clinical trial design before ultimately agreeing to review the application. Advisory panel members concluded that the vaccine’s benefits outweigh its risks, citing evidence that it produced stronger protection than standard-dose influenza vaccines among adults ages 50 to 64 and generated robust immune responses among older adults. If approved, mFlusiva would become the first mRNA-based seasonal influenza vaccine licensed in the United States, potentially opening a new chapter in vaccine development while also reigniting debates over mRNA technology, regulatory oversight, and public confidence in vaccination programs.

      Sources

      • https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement
      • https://www.reuters.com/legal/litigation/modernas-mrna-flu-vaccine-faces-fda-advisory-panel-scrutiny-2026-06-18
      • https://www.biopharminternational.com/view/fda-advisory-panel-convenes-today-to-weigh-moderna-s-mrna-based-flu-vaccine
      • https://www.biopharmadive.com/news/moderna-flu-vaccine-fda-advisory-committee-documents/823002

      Key Takeaways

      • FDA vaccine advisers voted unanimously that Moderna’s mFlusiva offers a favorable benefit-risk profile for adults aged 50 and older, placing the vaccine on a strong path toward approval.
      • Clinical trial data indicate the vaccine outperformed standard-dose flu shots in adults ages 50 to 64, while also generating strong immune responses in older populations.
      • The decision could establish the first licensed mRNA seasonal influenza vaccine in the United States, potentially expanding the role of mRNA technology beyond COVID-era applications while intensifying scrutiny of vaccine regulation and safety standards.

      In-Depth

      The unanimous vote by the FDA’s vaccine advisory committee in support of Moderna’s mFlusiva marks a significant moment in the continuing debate over both vaccine innovation and government oversight. While the recommendation does not guarantee approval, it substantially increases the likelihood that regulators will authorize the vaccine for use in adults 50 years of age and older later this year.

      For conservatives who have spent years demanding greater transparency and accountability from federal health agencies, the story is notable not simply because of the vaccine itself, but because of the process. Earlier this year, regulators questioned Moderna’s application and trial design, raising concerns that the company had used a standard-dose comparator vaccine rather than a high-dose option commonly recommended for some older adults. That dispute fueled concerns about scientific standards, regulatory consistency, and whether political considerations were influencing public health decisions. Ultimately, however, the FDA proceeded with a full review and advisory committee evaluation.

      The data presented to the panel appear to have persuaded committee members that the vaccine delivers measurable benefits. Supporters point to evidence that mFlusiva provided superior protection compared with conventional flu shots in adults ages 50 to 64 and demonstrated strong immune responses among seniors. Critics, meanwhile, continue to argue that long-term evidence remains limited because the efficacy data come primarily from a single influenza season.

      What happens next may be even more important. If approved, mFlusiva would become the first mRNA-based influenza vaccine available in the United States. That would represent a major expansion of a technology that remains controversial among many Americans. As federal officials weigh the final decision, the broader challenge remains balancing medical innovation with rigorous oversight, public trust, and a commitment to transparent science.

      Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
      Previous ArticleApple-Intel Chip Alliance Signals Major Return of U.S. Semiconductor Manufacturing
      Next Article U.S. Commits $500 Million to AI-Driven Push Against China’s Chip Material Dominance

      Related Posts

      Australia’s Greens Push 12-Month Smart Glasses Import Ban Over Privacy and Surveillance Concerns

      November 21, 2026

      Congressional Investigation Finds Major AI Platforms Can Generate Terrorist Attack Plans

      November 21, 2026

      Russian Agent Indicted for Stalking Silicon Valley Defense Workers After Illegally Entering US

      November 20, 2026

      Nvidia Halts U.S.-Approved AI Chip Shipments to China Amid Rising National Security Concerns

      November 20, 2026
      Add A Comment
      Leave A Reply Cancel Reply

      Editors Picks

      Australia’s Greens Push 12-Month Smart Glasses Import Ban Over Privacy and Surveillance Concerns

      November 21, 2026

      CISA Warns Critical Java4Shell Security Flaw Could Allow Hackers to Hijack Computer Systems

      November 21, 2026

      Apple Pay, iCloud and App Store Outage Disrupts Thousands After Internal System Update

      November 20, 2026

      FAA’s $875 Million AI Air Traffic System Faces Scrutiny After Nationwide Flight Ground Stop

      November 19, 2026
      Popular Topics
      Series B spotlight Tesla Tesla Cybertruck Satellite Space Taiwan Tech Tim Cook Viral Samsung starlink trending Startup UAE Tech Satya Nadella Software Stocks SpaceX Series A Sundar Pichai
      Major Tech Companies
      • Apple News
      • Google News
      • Meta News
      • Microsoft News
      • Amazon News
      • Samsung News
      • Nvidia News
      • OpenAI News
      • Tesla News
      • AMD News
      • Anthropic News
      • Elbit News
      AI & Emerging Tech
      • AI Regulation News
      • AI Safety News
      • AI Adoption
      • Quantum Computing News
      • Robotics News
      Key People
      • Sam Altman News
      • Jensen Huang News
      • Elon Musk News
      • Mark Zuckerberg News
      • Sundar Pichai News
      • Tim Cook News
      • Satya Nadella News
      • Mustafa Suleyman News
      Global Tech & Policy
      • Israel Tech News
      • India Tech News
      • Taiwan Tech News
      • UAE Tech News
      Startups & Emerging Tech
      • Series A News
      • Series B News
      • Startup News
      Tallwire
      Facebook X (Twitter) LinkedIn Threads Instagram RSS
      • AI
      • Tech
      • Business/Finance
      • Cybersecurity
      • Government
      • Legal
      • Health
      • Science
      • Academia
      • Entertainment/Communications
      • People
      • Transportation
      • Opinion
      • Press Kit
      © 2026 Tallwire. Optimized by ARMOUR Digital Marketing Agency.

      Type above and press Enter to search. Press Esc to cancel.